VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference

May, 18 2022

BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will present at the HC Wainwright & Co. Global Investment Conference on May 25, 2022. Management will also be available for one-on-one meetings with investors. HC Wainwright & Co. Global Investment Conference – Presentation Details Date: Wednesday, May 25, 2022 Time: 9:00 a.m. ET Webcast Link: https://journey.ct.events/view/f49ba6f9-4835-4fb5-9a1c-0c341c71da26 *a replay will be…

Read More

VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform

May, 10 2022

BRIDGEWATER, N.J., May 10, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that it will hold a virtual Key Opinion Leader (KOL) event on VYNE’s InhiBET™ BET Inhibitor Platform on Tuesday, May 17, 2022 at 10:00 a.m. ET. The agenda for the webinar will include an overview on pan-bromodomain and extra-terminal (“BET”) inhibition for the treatment of various immuno-inflammatory conditions, a review of the current treatment landscape and unmet medical need in treating patients with vitiligo, a discussion…

Read More

VYNE Therapeutics to Present at LifeSci Partners’ Immunology & Inflammation Symposium on May 10th

May, 06 2022

BRIDGEWATER, N.J., May 06, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will present at LifeSci Partners’ virtual Immunology and Inflammation Symposium, taking place May 10th-11th, 2022. Virtual Presentation Details     Date: Tuesday, May 10th Time: 1:30pm Eastern Time Webcast Link: VYNE Therapeutics Presentation The replay of the webcast will be available on the VYNE website for 90 days following the conference. About VYNE…

Read More

VYNE Therapeutics to Present at 42nd Annual Cowen Healthcare Conference

March, 03 2022

BRIDGEWATER, N.J., March 03, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, Chief Executive Officer, will participate in a virtual fireside chat at the 42nd Annual Cowen Healthcare Conference on March 8, 2022. Management will also be available for 1-on-1 meetings with investors. Virtual Presentation Details Date:   Tuesday, March 8th Time:   12:50 p.m. ET Format:   Virtual Fireside Chat Webcast Link:   https://wsw.com/webcast/cowen108/vyne/2045898 The replay of the webcast will be available on the…

Read More

VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access Event

January, 03 2022

BRIDGEWATER, N.J., Jan. 03, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that management will participate in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022. About VYNE Therapeutics Inc. VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary pipeline includes FMX114 for the potential treatment of mild-to-moderate atopic dermatitis and access to a library of bromodomain & extra-terminal (BET) domain inhibitors in both topical…

Read More

VYNE Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

November, 18 2021

BRIDGEWATER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference. The presentation will take the form of a pre-recorded fireside chat, which will be available on the Company’s website beginning November 22nd. Management will also be available for 1-on-1 meetings with investors during the conference November 29th – December 2nd. Presentation details     Date: Monday, November 22, 2021     Time: Beginning at 10:00 a.m. Eastern Time     Presentation Type: Pre-Recorded…

Read More